{"title_page": "Urelumab", "text_new": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 470620242\n| type              = mab\n| image             = \n| alt               = \n| mab_type          = mab\n| source            = u\n| target            = [[CD137]]\n| tradename         =  \n| Drugs.com         =\n| MedlinePlus       =\n| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      = <!-- A / B            / C / D / X -->\n| pregnancy_category=  \n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration = \n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| elimination_half-life = \n| excretion         = \n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number        = 934823-49-1\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 230902QLLC\n| ATC_prefix        = none\n| ATC_suffix        = \n| PubChem           = \n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = none\n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank          =\n| KEGG = D09984\n| C=6502 | H=9972 | N=1712 | O=2030 | S=44\n| synonyms = BMS-663513\n}}\n\n'''Urelumab''' ('''BMS-663513''' or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by [[Bristol-Myers Squibb]] for the treatment of cancer and solid tumors.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/urelumab.pdf}}</ref>\n\nUrelumab targets the extracellular domain of [[CD137]].<ref name=\":0\">{{Cite journal|last=Yonezawa|first=A.|last2=Dutt|first2=S.|last3=Chester|first3=C.|last4=Kim|first4=J.|last5=Kohrt|first5=H. E.|date=2015-07-15|title=Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy|url=http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-15-0263|journal=Clinical Cancer Research|language=en|volume=21|issue=14|pages=3113\u20133120|doi=10.1158/1078-0432.CCR-15-0263|issn=1078-0432|pmc=5422104}}</ref> It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a [[cytotoxic T cell]] response, against tumor cells.<ref>{{cite web|title= Urelumab|publisher=[[National Cancer Institute]]|url=http://www.cancer.gov/drugdictionary?cdrid=489120}}</ref>\n\nThe first phase I trial began in 2006 and final results were published in 2015.<ref>{{cite web|url=https://clinicaltrials.gov/ct2/show/NCT00309023|title=Study of BMS-663513 in Patients With Advanced Cancer - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov}}</ref>\n\nCurrent clinical trials combine urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab\n(NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.<ref name=\":0\" />\n\n==References==\n<references/>\n\n{{Monoclonals for immune system}}\n{{Cytokine receptor modulators}}\n\n[[Category:Bristol-Myers Squibb]]\n[[Category:Monoclonal antibodies]]\n[[Category:Experimental cancer drugs]]\n\n\n{{monoclonal-antibody-stub}}\n{{antineoplastic-drug-stub}}\n", "text_old": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 470620242\n| type              = mab\n| image             = \n| alt               = \n| mab_type          = mab\n| source            = u\n| target            = [[CD137]]\n| tradename         =  \n| Drugs.com         =\n| MedlinePlus       =\n| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      = <!-- A / B            / C / D / X -->\n| pregnancy_category=  \n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration = \n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| elimination_half-life = \n| excretion         = \n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number        = 934823-49-1\n| ATC_prefix        = none\n| ATC_suffix        = \n| PubChem           = \n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = none\n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank          =\n| KEGG = D09984\n| C=6502 | H=9972 | N=1712 | O=2030 | S=44\n| synonyms = BMS-663513\n}}\n\n'''Urelumab''' ('''BMS-663513''' or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by [[Bristol-Myers Squibb]] for the treatment of cancer and solid tumors.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/urelumab.pdf}}</ref>\n\nUrelumab targets the extracellular domain of [[CD137]].<ref name=\":0\">{{Cite journal|last=Yonezawa|first=A.|last2=Dutt|first2=S.|last3=Chester|first3=C.|last4=Kim|first4=J.|last5=Kohrt|first5=H. E.|date=2015-07-15|title=Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy|url=http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-15-0263|journal=Clinical Cancer Research|language=en|volume=21|issue=14|pages=3113\u20133120|doi=10.1158/1078-0432.CCR-15-0263|issn=1078-0432|pmc=5422104}}</ref> It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a [[cytotoxic T cell]] response, against tumor cells.<ref>{{cite web|title= Urelumab|publisher=[[National Cancer Institute]]|url=http://www.cancer.gov/drugdictionary?cdrid=489120}}</ref>\n\nThe first phase I trial began in 2006 and final results were published in 2015.<ref>{{cite web|url=https://clinicaltrials.gov/ct2/show/NCT00309023|title=Study of BMS-663513 in Patients With Advanced Cancer - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov}}</ref>\n\nCurrent clinical trials combine urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab\n(NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.<ref name=\":0\" />\n\n==References==\n<references/>\n\n{{Monoclonals for immune system}}\n{{Cytokine receptor modulators}}\n\n[[Category:Bristol-Myers Squibb]]\n[[Category:Monoclonal antibodies]]\n[[Category:Experimental cancer drugs]]\n\n\n{{monoclonal-antibody-stub}}\n{{antineoplastic-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Urelumab"}
